Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 2%

Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) were up 2% on Tuesday . The company traded as high as $2.64 and last traded at $2.55. Approximately 125,887 shares traded hands during trading, an increase of 180% from the average daily volume of 44,959 shares. The stock had previously closed at $2.50.

Reneo Pharmaceuticals Price Performance

The firm has a market cap of $62.55 million, a P/E ratio of -1.28 and a beta of 0.50. The stock’s 50-day simple moving average is $2.30 and its two-hundred day simple moving average is $2.91.

Reneo Pharmaceuticals (NASDAQ:RPHM – Get Rating) last released its quarterly earnings results on Tuesday, November 8th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.05. As a group, sell-side analysts expect that Reneo Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Institutional Trading of Reneo Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RPHM. Citadel Advisors LLC purchased a new stake in Reneo Pharmaceuticals in the 2nd quarter worth about $457,000. Millennium Management LLC purchased a new stake in Reneo Pharmaceuticals in the 2nd quarter worth about $158,000. UBS Group AG raised its position in Reneo Pharmaceuticals by 5,012.5% in the 2nd quarter. UBS Group AG now owns 54,550 shares of the company’s stock worth $145,000 after purchasing an additional 53,483 shares during the period. Renaissance Technologies LLC purchased a new stake in Reneo Pharmaceuticals in the 2nd quarter worth about $61,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Reneo Pharmaceuticals in the 3rd quarter worth about $62,000. 75.61% of the stock is owned by hedge funds and other institutional investors.

About Reneo Pharmaceuticals

(Get Rating)

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.